RU2020103379A3 - - Google Patents

Download PDF

Info

Publication number
RU2020103379A3
RU2020103379A3 RU2020103379A RU2020103379A RU2020103379A3 RU 2020103379 A3 RU2020103379 A3 RU 2020103379A3 RU 2020103379 A RU2020103379 A RU 2020103379A RU 2020103379 A RU2020103379 A RU 2020103379A RU 2020103379 A3 RU2020103379 A3 RU 2020103379A3
Authority
RU
Russia
Application number
RU2020103379A
Other languages
Russian (ru)
Other versions
RU2020103379A (ru
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of RU2020103379A publication Critical patent/RU2020103379A/ru
Publication of RU2020103379A3 publication Critical patent/RU2020103379A3/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/90—Isomerases (5.)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y503/00—Intramolecular oxidoreductases (5.3)
    • C12Y503/03—Intramolecular oxidoreductases (5.3) transposing C=C bonds (5.3.3)
    • C12Y503/03012—L-Dopachrome isomerase (5.3.3.12)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/605—MHC molecules or ligands thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
RU2020103379A 2017-07-04 2018-07-03 Новые молекулы нуклеиновых кислот RU2020103379A (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EPPCT/EP2017/066676 2017-07-04
EPPCT/EP2017/066676 2017-07-04
PCT/EP2018/068015 WO2019008001A1 (en) 2017-07-04 2018-07-03 NEW NUCLEIC ACID MOLECULES

Publications (2)

Publication Number Publication Date
RU2020103379A RU2020103379A (ru) 2021-08-04
RU2020103379A3 true RU2020103379A3 (cg-RX-API-DMAC7.html) 2021-12-07

Family

ID=59384128

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2020103379A RU2020103379A (ru) 2017-07-04 2018-07-03 Новые молекулы нуклеиновых кислот

Country Status (12)

Country Link
US (2) US10988754B2 (cg-RX-API-DMAC7.html)
EP (3) EP3648791A1 (cg-RX-API-DMAC7.html)
JP (2) JP7722629B2 (cg-RX-API-DMAC7.html)
KR (1) KR102761594B1 (cg-RX-API-DMAC7.html)
CN (1) CN111328287A (cg-RX-API-DMAC7.html)
AU (1) AU2018298422B2 (cg-RX-API-DMAC7.html)
BR (1) BR112019028280A2 (cg-RX-API-DMAC7.html)
CA (1) CA3066932A1 (cg-RX-API-DMAC7.html)
ES (1) ES3013993T3 (cg-RX-API-DMAC7.html)
RU (1) RU2020103379A (cg-RX-API-DMAC7.html)
SG (1) SG11201911430PA (cg-RX-API-DMAC7.html)
WO (1) WO2019008001A1 (cg-RX-API-DMAC7.html)

Families Citing this family (179)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012019630A1 (en) 2010-08-13 2012-02-16 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded protein
WO2012116714A1 (en) 2011-03-02 2012-09-07 Curevac Gmbh Vaccination in elderly patients
SMT202200355T1 (it) * 2011-12-16 2022-11-18 Modernatx Inc Composizioni di mrna modificato
WO2013120499A1 (en) 2012-02-15 2013-08-22 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly (a) sequence or a polyadenylation signal for increasing the expression of an encoded pathogenic antigen
MX2019002345A (es) 2012-03-27 2022-08-24 Curevac Ag Moleculas artificiales de acido nucleico para la expresion mejorada de proteina o peptido.
MX385338B (es) 2013-02-22 2025-03-18 CureVac SE Combinación de vacunación e inhibición de la trayectoria pd-1.
ES2747762T3 (es) 2013-08-21 2020-03-11 Curevac Ag Vacuna contra el virus respiratorio sincitial (RSV)
WO2015024669A1 (en) 2013-08-21 2015-02-26 Curevac Gmbh Combination vaccine
WO2015024665A1 (en) 2013-08-21 2015-02-26 Curevac Gmbh Rabies vaccine
ES2754239T3 (es) 2014-03-12 2020-04-16 Curevac Ag Combinación de vacunación y agonistas de OX40
DK3708668T3 (da) 2014-12-12 2022-09-26 Curevac Ag Kunstigt nukleinsyremolekyle til forbedret proteinudtrykkelse
EP4461371A3 (en) 2014-12-23 2025-02-26 immatics biotechnologies GmbH Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (hcc) and other cancers
GB201501017D0 (en) 2014-12-23 2015-03-04 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers
EP3294885B1 (en) 2015-05-08 2020-07-01 CureVac Real Estate GmbH Method for producing rna
DE202016009003U1 (de) 2015-05-29 2021-05-28 Curevac Real Estate Gmbh Zusammensetzung umfassend in vitro transkribierte RNA erhältlich durch ein Verfahren zur Herstellung und Reinigung von RNA mit mindestens einem Schritt mit einer tangentialen Flussfiltration
GB201513921D0 (en) * 2015-08-05 2015-09-23 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
EP3362576A1 (en) 2015-10-12 2018-08-22 CureVac AG Automated method for isolation, selection and/or detection of microorganisms or cells comprised in a solution
US11413346B2 (en) 2015-11-09 2022-08-16 Curevac Ag Rotavirus vaccines
IL298653A (en) 2015-12-11 2023-01-01 Immatics Biotechnologies Gmbh New peptides and a combination of peptides for use in immunotherapy against several types of cancer
US11684665B2 (en) 2015-12-22 2023-06-27 CureVac SE Method for producing RNA molecule compositions
US11248223B2 (en) 2015-12-23 2022-02-15 Curevac Ag Method of RNA in vitro transcription using a buffer containing a dicarboxylic acid or tricarboxylic acid or a salt thereof
WO2017140905A1 (en) 2016-02-17 2017-08-24 Curevac Ag Zika virus vaccine
WO2017149139A1 (en) 2016-03-03 2017-09-08 Curevac Ag Rna analysis by total hydrolysis
GB201604458D0 (en) 2016-03-16 2016-04-27 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against cancers
GB201604490D0 (en) 2016-03-16 2016-04-27 Immatics Biotechnologies Gmbh Peptides combination of peptides for use in immunotherapy against cancers
EP3448427A1 (en) 2016-04-29 2019-03-06 CureVac AG Rna encoding an antibody
US11141474B2 (en) 2016-05-04 2021-10-12 Curevac Ag Artificial nucleic acid molecules encoding a norovirus antigen and uses thereof
EP3452101A2 (en) 2016-05-04 2019-03-13 CureVac AG Rna encoding a therapeutic protein
BR112018075479A2 (pt) 2016-06-09 2019-03-19 Curevac Ag portadores híbridos para carga de ácido nucleico
US11279923B2 (en) 2016-11-28 2022-03-22 Curevac Ag Method for purifying RNA
WO2018104538A1 (en) 2016-12-08 2018-06-14 Curevac Ag Rna for treatment or prophylaxis of a liver disease
DE102016123893A1 (de) 2016-12-08 2018-06-14 Immatics Biotechnologies Gmbh T-Zellrezeptoren mit verbesserter Bindung
WO2018104540A1 (en) 2016-12-08 2018-06-14 Curevac Ag Rnas for wound healing
EP3558355A2 (en) 2016-12-23 2019-10-30 CureVac AG Henipavirus vaccine
EP3558356A2 (en) 2016-12-23 2019-10-30 CureVac AG Mers coronavirus vaccine
WO2018115525A1 (en) 2016-12-23 2018-06-28 Curevac Ag Lassa virus vaccine
JP2020513824A (ja) 2017-03-24 2020-05-21 キュアバック アーゲー Ｃｒｉｓｐｒ関連タンパク質をコードする核酸、及びその使用
US11357856B2 (en) 2017-04-13 2022-06-14 Acuitas Therapeutics, Inc. Lipids for delivery of active agents
CN108728477B (zh) * 2017-04-24 2022-02-22 华东理工大学 一种高效的转座突变系统及构建方法
WO2018211038A1 (en) 2017-05-17 2018-11-22 Curevac Ag Method for determining at least one quality parameter of an rna sample
WO2019005822A1 (en) 2017-06-28 2019-01-03 The Cleveland Clinic Foundation TREATMENT OF AN INJURY OF THE NERVOUS SYSTEM AND NEURODEGENERATIVE DISORDERS AND ASSOCIATED DISORDERS
JP2020530759A (ja) 2017-07-07 2020-10-29 イマティクス バイオテクノロジーズ ゲーエムベーハー Ｎｓｃｌｃ、ｓｃｌｃ、およびその他のがんをはじめとする肺がんに対する免疫療法で使用するための新規ペプチドおよびペプチド併用
EP3673069A1 (en) 2017-08-22 2020-07-01 CureVac AG Bunyavirales vaccine
JP2021502079A (ja) 2017-11-08 2021-01-28 キュアバック アーゲー ＲＮＡ配列の適合（Ａｄａｐｔａｔｉｏｎ）
EP3723796A1 (en) 2017-12-13 2020-10-21 CureVac AG Flavivirus vaccine
CN111511928A (zh) 2017-12-21 2020-08-07 库瑞瓦格股份公司 偶联到单一支持物或标签的线性双链dna和用于制备所述线性双链dna的方法
DE202019006108U1 (de) 2018-04-17 2024-12-16 CureVac SE Neue RSV-RNA-Moleküle und Zusammensetzungen für die Impfung
EP3814495B1 (en) 2018-06-28 2023-06-07 CureVac RNA Printer GmbH Bioreactor for rna in vitro transcription
US10925947B2 (en) 2018-06-29 2021-02-23 Immatics Biotechnologies Gmbh A*03 restricted peptides for use in immunotherapy against cancers and related methods
TW202024121A (zh) 2018-09-18 2020-07-01 德商英麥提克生物技術股份有限公司 A*01 限制肽和肽組合物在抗癌免疫治療中的用途和相關方法
TW202039534A (zh) * 2018-12-14 2020-11-01 美商美國禮來大藥廠 KRAS變體mRNA分子
WO2020127959A1 (en) 2018-12-21 2020-06-25 Curevac Ag Methods for rna analysis
EP3683229A1 (en) * 2019-01-21 2020-07-22 Charité - Universitätsmedizin Berlin Specific t cell receptors against epitopes of mutant myd88l265p protein for adoptive t cell therapy
CN111466338B (zh) * 2019-01-23 2022-03-22 中国科学院广州生物医药与健康研究院 Ddx5基因缺失的生精障碍小鼠模型及其构建方法
US20220177891A1 (en) * 2019-02-19 2022-06-09 Board Of Regents, The University Of Texas System Hipk inhibitors and methods of use thereof
CN109777783B (zh) * 2019-02-20 2023-07-04 上海尚泰生物技术有限公司 表达cxcr2的car-nk92细胞、制备方法及其应用
CN111620934B (zh) * 2019-02-26 2022-03-08 中国科学院遗传与发育生物学研究所 蛋白GmHSFB2b在调控植物黄酮类化合物积累中应用
CN110093419B (zh) * 2019-04-26 2023-10-27 北京大学深圳医院 环状rna的应用、试剂盒和药物组合物及其应用
CN114072175A (zh) * 2019-07-04 2022-02-18 江苏康宁杰瑞生物制药有限公司 治疗肿瘤的物质和方法
CN112175062B (zh) * 2019-07-05 2022-07-15 中国医学科学院基础医学研究所 Sft2b蛋白线性抗原表位以及其在精神分裂症诊断中的用途
WO2021041541A1 (en) * 2019-08-28 2021-03-04 The Board Of Trustees Of The Leland Stanford Junior University Modified circular rnas and methods of use thereof
WO2021081058A1 (en) * 2019-10-21 2021-04-29 Translate Bio, Inc. Compositions, methods and uses of messenger rna
KR20220113485A (ko) * 2019-12-11 2022-08-12 아벨리노 랩 유에스에이, 인크. 짧은 간섭 rna를 사용한 r124h 돌연변이에 의한 형질전환 성장 인자 베타 유도된 유전자의 대립유전자-특이적 사일런싱
CN111057690A (zh) * 2019-12-23 2020-04-24 维塔恩(广州)医药有限公司 肿瘤相关基因braf突变相关抗原短肽及其应用
US12194089B2 (en) 2020-02-04 2025-01-14 CureVac SE Coronavirus vaccine
US11241493B2 (en) 2020-02-04 2022-02-08 Curevac Ag Coronavirus vaccine
CN111647598B (zh) * 2020-02-11 2022-09-06 昆明医科大学 一种抑制hsa_circ_0027477表达的siRNA及其应用
CN111118011B (zh) * 2020-02-11 2022-09-06 昆明医科大学 一种抑制hsa_circ_0027478表达的siRNA及其应用
CN111733158B (zh) * 2020-02-11 2022-09-06 昆明医科大学 一种抑制hsa_circ_0003599表达的siRNA及其应用
CN111647597B (zh) * 2020-02-11 2022-09-06 昆明医科大学 一种抑制hsa_circ_0027479表达的siRNA及其应用
CN111337678B (zh) * 2020-02-21 2023-06-06 杭州凯保罗生物科技有限公司 与肿瘤免疫治疗效果相关的生物标志物及其应用
CN113874507A (zh) 2020-04-09 2021-12-31 苏州艾博生物科技有限公司 冠状病毒的核酸疫苗
EP4175967A2 (en) 2020-07-02 2023-05-10 Life Technologies Corporation Trinucleotide cap analogs, preparation and uses thereof
CN111840303A (zh) * 2020-07-15 2020-10-30 天津大学 胞质羧肽酶抑制剂及其应用
CN111984622B (zh) * 2020-07-31 2023-10-31 上海派拉软件股份有限公司 Pap的配置及运行方法、装置、电子设备和存储介质
CN116635525A (zh) * 2020-08-21 2023-08-22 北京大学 环状rna疫苗及其使用方法
CN112011564A (zh) * 2020-09-04 2020-12-01 西南大学 新型隐球菌细胞核指示载体及其构建方法和应用
CN111973745B (zh) * 2020-09-08 2022-07-26 中国医科大学 Bap18在乳腺癌内分泌治疗抵抗中的应用
CN114225035B (zh) * 2020-09-09 2022-12-16 上海交通大学医学院 环状RNA Cwc27下调剂在制备预防和/或治疗阿尔茨海默病的药物中的应用
DE102020125457A1 (de) * 2020-09-29 2022-03-31 Immatics Biotechnologies Gmbh Amidierte Peptide und ihre deamidierten Gegenstücke, die durch HLA-A*02-Moleküle präsentiert werden, zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten
CN112574975B (zh) * 2020-09-30 2022-04-01 华南理工大学 甘油酯脂肪酶突变体g28c-p206c及其编码基因与应用
CN112050201B (zh) * 2020-10-10 2022-04-12 清华大学 一种异型炉膛结构的湍动流化床焚烧炉
CN112190719B (zh) * 2020-10-19 2023-07-04 重庆大学 一种钙调控机制紊乱的动物模型在视网膜病变中的应用
CN112375766B (zh) * 2020-12-02 2022-04-29 华南农业大学 一种水稻抗氧化能力相关基因brhis1及其应用
CN112480232B (zh) * 2020-12-14 2022-07-15 上海交通大学 一种生物活性肽vsladlqndevafr及其制备方法和应用
CN112961247A (zh) * 2020-12-17 2021-06-15 维亚生物科技(上海)有限公司 一种融合蛋白及其应用
CN112575003B (zh) * 2020-12-17 2022-02-15 中国农业科学院植物保护研究所 本氏烟hakai基因在调控植物抗病毒中的应用及转基因植物培育方法
US11918643B2 (en) 2020-12-22 2024-03-05 CureVac SE RNA vaccine against SARS-CoV-2 variants
CN112630449B (zh) * 2020-12-30 2022-10-18 广西壮族自治区水牛研究所 对水牛出生时间进行判断的血液外泌体标志物及其应用
CN112662680B (zh) * 2020-12-31 2022-07-05 浙江大学 番茄黄化转绿基因SlRHBDD2及其应用
CN112763714B (zh) * 2020-12-31 2022-07-01 徐州市中心医院 一种用于肝癌诊断的生物标志物及其检测方法
CN112794901B (zh) * 2021-01-08 2022-01-04 南通大学附属医院 一种抗smim15单克隆抗体及其应用
CN112362432B (zh) * 2021-01-12 2021-04-09 广州科方生物技术股份有限公司 一种通用于血清中tt3和tt4的解离剂及其制备方法
CN114762694B (zh) * 2021-01-13 2023-07-14 中国人民解放军军事科学院军事医学研究院 寡糖转移酶抑制剂在预防和/或治疗新型冠状病毒感染中的应用
CN112626236A (zh) * 2021-01-14 2021-04-09 华南农业大学 与奶牛乳腺上皮细胞凋亡相关的circRNA标志物及其应用
CN112679596B (zh) * 2021-01-15 2022-03-15 武汉大学 一种内收蛋白的抗原肽及其抗体与应用
CN112574997B (zh) * 2021-01-17 2023-07-21 楷拓生物科技(苏州)有限公司 一种fbxw7环状rna的改构体及其在肿瘤药物和新冠疫苗中的应用
CN112852698B (zh) * 2021-01-30 2022-11-29 军事科学院军事医学研究院军事兽医研究所 牛种布鲁氏菌A19株asd基因缺失株的构建方法和应用
CN112795642A (zh) * 2021-02-09 2021-05-14 四川大学华西医院 鉴定家族性渗出性玻璃体视网膜病变伴/不伴小头畸形的引物及其应用
WO2022173730A1 (en) * 2021-02-09 2022-08-18 Virginia Commonwealth University Mini circular rna therapeutics and vaccines and methods of use thereof
US20220372165A1 (en) 2021-05-05 2022-11-24 Immatics Biotechnologies Gmbh Antigen binding proteins specifically binding prame
CN113373129B (zh) * 2021-05-25 2022-07-26 湖北大学 一种原核生物来源的Mbp_Argonaute蛋白及其应用
CN113393900B (zh) * 2021-06-09 2022-08-02 吉林大学 基于改进Transformer模型的RNA状态推断研究方法
CN115491369B (zh) * 2021-06-18 2025-06-03 佛山热休生物技术有限公司 Pdia3的表位肽及所述表位肽与热休克蛋白的复合物
CN113450872B (zh) * 2021-07-02 2022-12-02 南昌大学 磷酸化位点特异激酶的预测方法
CN113687076B (zh) * 2021-07-14 2024-03-01 郑州大学 一种可用于肺腺癌早期诊断的联合检测血清标志物及其应用
CN117980322A (zh) * 2021-07-23 2024-05-03 卡萨瓦科学公司 用于阿尔茨海默病的基于血液的诊断测定
WO2023014598A2 (en) * 2021-08-03 2023-02-09 Inflammatix, Inc. Isothermal amplification-based diagnosis and treatment of acute infection
CN113846122B (zh) * 2021-08-16 2023-08-25 中国医学科学院医学生物学研究所 一种过表达snca的腺相关病毒载体aav-snca、制备方法及其应用
AU2021461416A1 (en) 2021-08-24 2024-02-22 BioNTech SE In vitro transcription technologies
CN113533589B (zh) * 2021-09-16 2021-12-17 天九再生医学(天津)科技有限公司 一种分析外泌体电荷异质性的方法
CN114457052B (zh) * 2021-09-17 2024-02-27 厦门大学 一种抗肿瘤的多肽组合物及其应用
EP4422698A1 (en) 2021-10-29 2024-09-04 CureVac SE Improved circular rna for expressing therapeutic proteins
CA3238757A1 (en) 2021-11-29 2023-06-01 Alexander Muik Coronavirus vaccine
CN114134109B (zh) * 2021-12-10 2023-01-24 广州远想生物科技股份有限公司 Egf间充质干细胞外泌体的纯化方法
KR102818855B1 (ko) * 2021-12-13 2025-06-16 주식회사 에스엠엘바이오팜 발현 효율을 증가시킨 핵산 발현 플랫폼
CN114262378B (zh) * 2021-12-20 2023-03-24 南京诺唯赞生物科技股份有限公司 一种omt的单克隆抗体及其制备方法
CA3243030A1 (en) * 2021-12-21 2025-02-26 Amgen Inc. DCAF4L2 SPECIFIC T LYMPHOCYTE RECEPTORS
CN114276418B (zh) * 2021-12-28 2024-06-25 中国科学技术大学 一种可用于调控微管、治疗脱髓鞘病变靶向治疗的rna
CN114350800B (zh) * 2021-12-29 2024-03-19 中南大学湘雅医院 Sphk1在制备pd-l1/pd-1单抗肿瘤免疫治疗药物中的应用
CN114410778B (zh) * 2021-12-29 2024-03-19 中南大学湘雅医院 Pf543在制备pd-l1/pd-1单抗肿瘤免疫治疗药物中的应用
CN114384032B (zh) * 2022-01-17 2023-07-14 云南大学 诺如病毒检测探针和非诊断目的检测诺如病毒的方法
US20250108134A1 (en) * 2022-01-28 2025-04-03 Beijing Changping Laboratory Circular rna vaccines and methods of use thereof
JP2025503994A (ja) 2022-01-28 2025-02-06 ビオンテック・ソシエタス・エウロパエア コロナウイルスワクチン
CN115058388A (zh) * 2022-03-14 2022-09-16 福建医科大学附属协和医院 间充质干细胞创面修复优势功能亚群及其鉴定和应用
CN114561389A (zh) * 2022-03-15 2022-05-31 南通市肿瘤医院 Vrk1表达抑制剂及其应用
CN114621962B (zh) * 2022-03-21 2024-05-14 广西大学 花生AhBI-1基因VIGS沉默体系
US12416044B2 (en) * 2022-03-21 2025-09-16 Abclonal Science, Inc. T4 DNA ligase variants with increased ligation efficiency
CN114410607A (zh) * 2022-03-22 2022-04-29 上海威高医疗技术发展有限公司 嗜热羧酸酯酶突变体及其应用
CN119403568A (zh) * 2022-04-07 2025-02-07 艾丽塔生物治疗剂公司 用于治疗癌症的组合物和方法
US20250251394A1 (en) * 2022-04-12 2025-08-07 Concordia University Aptamer-based electrochemical drug detection assay
CN115219720A (zh) * 2022-05-20 2022-10-21 上饶师范学院 靶向分子atx在乙肝阳性肝癌中的应用及其研究方法
CN114702569B (zh) * 2022-05-25 2023-01-10 深圳吉诺因生物科技有限公司 Pd-l1相关疫苗及其应用
CN114703287B (zh) * 2022-06-06 2022-08-12 江苏省肿瘤医院 CXorf56基因在治疗三阴性乳腺癌中的应用
US11878055B1 (en) 2022-06-26 2024-01-23 BioNTech SE Coronavirus vaccine
CN114916502B (zh) * 2022-07-07 2023-06-16 电子科技大学 一种视网膜色素变性疾病模型的构建方法和应用
CN116286990A (zh) * 2022-09-08 2023-06-23 南开大学 特异性靶向肿瘤和转移抑制的细胞膜来源纳米囊泡的制备方法与应用
UY40490A (es) 2022-10-17 2024-04-30 Pfizer Vacunas de combinación para prevenir y/o tratar múltiples agentes infecciosos
WO2024083345A1 (en) 2022-10-21 2024-04-25 BioNTech SE Methods and uses associated with liquid compositions
WO2024089638A1 (en) 2022-10-28 2024-05-02 Glaxosmithkline Biologicals Sa Nucleic acid based vaccine
CN116254253B (zh) * 2022-11-11 2024-06-28 浙大宁波理工学院 一种通过dna合成改组组合突变获得的谷氨酸脱羧酶突变体及应用
CN115472216B (zh) * 2022-11-14 2023-03-24 神州医疗科技股份有限公司 基于数据集成的肿瘤跨适应症联合用药推荐方法和系统
CN116083353B (zh) * 2022-12-02 2025-10-17 唐颐生物医学(天津)有限公司 一种过表达Anxa1的脐带间充质干细胞外泌体及其制备方法和应用
CN115814605B (zh) * 2022-12-06 2024-04-12 浙江大学 一种废弃反渗透膜修复剂及修复方法
CN116271007B (zh) * 2022-12-26 2025-10-03 浙江大学 一种用于治疗炎症性肠病的药物
CN116236584B (zh) * 2023-02-20 2024-03-22 四川大学 一种用于高效递送siRNA的多糖-多肽偶联物
CN116334083B (zh) * 2023-02-24 2025-06-20 青岛农业大学 花生U6启动子及其在花生CRISPR-Cas9基因编辑中的应用
CN116474080B (zh) * 2023-04-20 2023-12-22 新疆农垦科学院 一种细粒棘球绦虫表面展示型酿酒酵母口服疫苗及其构建方法和应用
NL2034658B1 (en) * 2023-04-21 2024-10-28 Academisch Ziekenhuis Leiden TIMP3-derived TEIPP neoantigens and uses thereof
CN116555286B (zh) * 2023-04-28 2024-05-14 昆明理工大学 三七富含脯氨酸蛋白基因PnPRPL1及其应用
CN116514115B (zh) * 2023-05-05 2025-05-13 大连医科大学 一种巯基烟酸与金纳米粒子修饰氧化石墨烯材料及其制备方法和应用
US12502424B2 (en) 2023-05-05 2025-12-23 Sanofi Pasteur Inc. Compositions for use in treatment of acne
AU2024278682A1 (en) 2023-05-26 2025-11-27 CureVac SE Cancer antigens
CN116637123B (zh) * 2023-06-07 2024-02-13 上海市东方医院（同济大学附属东方医院） 敲降或下调C15orf39基因表达的试剂在制备治疗胃癌的药物中的应用
EP4484954A1 (en) * 2023-06-29 2025-01-01 Uniwersytet Gdanski Mhc class i restricted immunopeptide pattern for generation of anti-nsclc vaccines
WO2025064738A1 (en) * 2023-09-22 2025-03-27 Regeneron Pharmaceuticals, Inc. Dntt 250-258 off-target peptides and uses thereof
CN117169519B (zh) * 2023-10-26 2024-01-30 艾康生物技术(杭州)有限公司 用于检测样本中tt3和/或tt4的解离剂和试剂盒
WO2025103803A1 (en) 2023-11-13 2025-05-22 CureVac SE Immunotherapy against neuronal and brain tumors
CN117230077B (zh) * 2023-11-13 2024-02-23 四川省医学科学院·四川省人民医院 Hakai基因在RP疾病模型构建中的应用及构建方法
WO2025131119A1 (en) * 2023-12-22 2025-06-26 Everest Medicines (China) Co., Ltd. Cancer vaccines and uses thereof
WO2025140126A1 (en) * 2023-12-25 2025-07-03 Everest Medicines (China) Co., Ltd. Therapeutic ly6k mrna vaccine for cancer
WO2025146130A1 (en) * 2024-01-04 2025-07-10 Everest Medicines (China) Co., Ltd. Therapeutic BIRC5 mRNA Vaccine for Cancer
WO2025146077A1 (en) * 2024-01-04 2025-07-10 Everest Medicines (China) Co., Ltd. Cancer vaccines and uses thereof
WO2025148611A1 (zh) * 2024-01-12 2025-07-17 新牛（郑州）生物科技有限公司 肿瘤抗原肽融合蛋白及其组合物的基因工程化递送和应用
CN117986344B (zh) * 2024-02-05 2025-12-02 浙江大学 一种靶向线粒体核糖核酸酶p的多肽及应用
CN118516398B (zh) * 2024-02-26 2025-04-22 四川农业大学 水稻OsMED23基因、其编码蛋白及其应用
CN118389553A (zh) * 2024-03-01 2024-07-26 中国科学技术大学 免疫增效rna分子及其组合物、疫苗与试剂盒
KR20250148433A (ko) * 2024-03-29 2025-10-14 한미약품 주식회사 복수 kras 변이 펩티드가 연결된 항원 펩티드, 이를 코딩하는 핵산 및 이의 용도
CN118006766B (zh) * 2024-04-09 2024-06-28 鄂尔多斯市中心医院（内蒙古自治区超声影像研究所） Pola2在诊断代谢综合征中的应用
CN118546871B (zh) * 2024-05-10 2025-05-06 未来智人再生医学研究院(广州)有限公司 一种人多能干细胞分化为间充质干细胞的方法
WO2025242815A1 (en) 2024-05-23 2025-11-27 CureVac SE Immunotherapy of squamous cell carcinoma
CN118460649B (zh) * 2024-07-10 2024-12-13 凯莱英医药集团（天津）股份有限公司 一种Vutrisiran的制备方法
CN118530376B (zh) * 2024-07-26 2024-11-26 英特菲尔(成都)生物制品有限责任公司 一种具有修复抗皱活性的弹性蛋白及其制备方法与应用
CN119082106B (zh) * 2024-07-30 2025-09-30 福建中医药大学 一种抑制pno1基因表达的核酸分子及相关产品和用途
CN118879730B (zh) * 2024-08-08 2025-03-21 宁波大学 小麦TaHAKAI基因在调控小麦黄花叶病抗性中的应用
CN119464240B (zh) * 2024-08-19 2025-11-07 浙江理工大学绍兴生物医药研究院有限公司 一种突变型高稳定的过氧化氢酶及其构建方法
CN119464217A (zh) * 2024-11-01 2025-02-18 天津外泌体科技有限公司 一种囊泡及其作为标准品的应用
CN119390756B (zh) * 2024-11-04 2025-12-09 南京大学 一类基于d构型二苯丙氨酸的拟肽及其应用
CN119120482B (zh) * 2024-11-08 2025-02-14 中国医学科学院医学生物学研究所 E3泛素连接酶rnf181基因表达抑制剂在制备预防和/或治疗hsv-1病毒感染药物中的应用

Family Cites Families (172)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU649066B2 (en) 1990-07-25 1994-05-12 Syngene, Inc. Circular extension for generating multiple nucleic acid complements
US5633234A (en) * 1993-01-22 1997-05-27 The Johns Hopkins University Lysosomal targeting of immunogens
US5773244A (en) 1993-05-19 1998-06-30 Regents Of The University Of California Methods of making circular RNA
WO1995007707A1 (en) 1993-09-14 1995-03-23 Cytel Corporation Alteration of immune response using pan dr-binding peptides
US5534499A (en) 1994-05-19 1996-07-09 The University Of British Columbia Lipophilic drug derivatives for use in liposomes
US5820873A (en) 1994-09-30 1998-10-13 The University Of British Columbia Polyethylene glycol modified ceramide lipids and liposome uses thereof
US5885613A (en) 1994-09-30 1999-03-23 The University Of British Columbia Bilayer stabilizing components and their use in forming programmable fusogenic liposomes
DE69737659T2 (de) 1996-06-14 2007-12-27 Meiji Dairies Corp. Peptide aus t-zellepitopen
JP4382163B2 (ja) * 1997-03-27 2009-12-09 ザ カウンシル オブ ザ クイーンズランド インスティチュート オブ メディカル リサーチ ターゲッティング分子を用いた免疫応答の増強
US6320017B1 (en) 1997-12-23 2001-11-20 Inex Pharmaceuticals Corp. Polyamide oligomers
JP2002520000A (ja) * 1998-05-13 2002-07-09 エピミューン， インコーポレイテッド 免疫応答を刺激するための発現ベクターおよびそのベクターの使用方法
US6210931B1 (en) 1998-11-30 2001-04-03 The United States Of America As Represented By The Secretary Of Agriculture Ribozyme-mediated synthesis of circular RNA
EP1246597B1 (en) 1999-08-03 2015-01-14 The Ohio State University Polypeptides and polynucleotides for enhancing immune reactivity to her-2 protein
HUP0300067A3 (en) 2000-02-21 2010-03-29 Lundbeck & Co As H Novel method for down-regulation of amyloid
AU2001278117A1 (en) 2000-08-03 2002-02-18 Johns Hopkins University Molecular vaccine linking an endoplasmic reticulum chaperone polypeptide to an antigen
US20030138769A1 (en) 2000-08-16 2003-07-24 Birkett Ashley J. Immunogenic HBc chimer particles having enhanced stability
US20030091590A1 (en) * 2001-01-17 2003-05-15 Pomerantz Roger J. Recombinant rhabdoviruses as live-viral vaccines
ATE463505T1 (de) * 2001-04-20 2010-04-15 Inst Systems Biology Toll-ähnlichen-rezeptor-5-liganden und verwendungsverfahren
EP2305699B1 (de) 2001-06-05 2014-08-13 CureVac GmbH Stabilisierte mRNA mit erhöhtem G/C-Gehalt und optimierter Codon Usage für die Impfung gegen Schlafkrankheit, Leishmaniose und Toxoplasmose
DE10162480A1 (de) 2001-12-19 2003-08-07 Ingmar Hoerr Die Applikation von mRNA für den Einsatz als Therapeutikum gegen Tumorerkrankungen
AU2003277865B2 (en) 2002-06-25 2008-08-21 City Of Hope Adjuvant-free peptide vaccine
DE10229872A1 (de) 2002-07-03 2004-01-29 Curevac Gmbh Immunstimulation durch chemisch modifizierte RNA
EP2308968A1 (en) * 2002-11-26 2011-04-13 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
CU23204A1 (es) 2002-12-27 2007-05-18 Ct Ingenieria Genetica Biotech Combinaciones de factores reguladores del crecimiento y hormonas para el tratamiento de neoplasias
DE10335833A1 (de) 2003-08-05 2005-03-03 Curevac Gmbh Transfektion von Blutzellen mit mRNA zur Immunstimulation und Gentherapie
DE10347710B4 (de) * 2003-10-14 2006-03-30 Johannes-Gutenberg-Universität Mainz Rekombinante Impfstoffe und deren Verwendung
DE102004042546A1 (de) 2004-09-02 2006-03-09 Curevac Gmbh Kombinationstherapie zur Immunstimulation
US20090214598A1 (en) 2005-04-19 2009-08-27 Eli Lilly And Company Monovalent and polyvalent synthetic polysaccharide antigens for immunological intervention in disease
DE102005023170A1 (de) 2005-05-19 2006-11-23 Curevac Gmbh Optimierte Formulierung für mRNA
PL2578685T3 (pl) * 2005-08-23 2020-01-31 The Trustees Of The University Of Pennsylvania Rna zawierający zmodyfikowane nukleozydy i sposoby jego zastosowania
MX2008012392A (es) * 2006-03-27 2008-12-17 Globeimmune Inc Mutacion de ras, y composiciones y metodos relacionados con la misma.
JP2009544754A (ja) 2006-07-28 2009-12-17 アプライド バイオシステムズ， エルエルシー ジヌクレオチドｍｒｎａキャップアナログ
DE102006035618A1 (de) 2006-07-31 2008-02-07 Curevac Gmbh Nukleinsäure der Formel (I): GlXmGn, insbesondere als immunstimulierendes Adjuvanz
JP5750600B2 (ja) 2006-08-11 2015-07-22 ライフ・サイエンシーズ・リサーチ・パートナーズ・フェレニゲング・ゾンデル・ウィンストーメルクＬｉｆｅ Ｓｃｉｅｎｃｅｓ Ｒｅｓｅａｒｃｈ Ｐａｒｔｎｅｒｓ Ｖｚｗ 免疫原性ペプチドおよび免疫障害におけるその使用
DE102006061015A1 (de) 2006-12-22 2008-06-26 Curevac Gmbh Verfahren zur Reinigung von RNA im präparativen Maßstab mittels HPLC
DE102007001370A1 (de) 2007-01-09 2008-07-10 Curevac Gmbh RNA-kodierte Antikörper
WO2008157688A2 (en) 2007-06-19 2008-12-24 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Synthesis and use of anti-reverse phosphorothioate analogs of the messenger rna cap
WO2009030254A1 (en) 2007-09-04 2009-03-12 Curevac Gmbh Complexes of rna and cationic peptides for transfection and for immunostimulation
WO2009046738A1 (en) 2007-10-09 2009-04-16 Curevac Gmbh Composition for treating lung cancer, particularly of non-small lung cancers (nsclc)
WO2009046739A1 (en) 2007-10-09 2009-04-16 Curevac Gmbh Composition for treating prostate cancer (pca)
JP5749494B2 (ja) 2008-01-02 2015-07-15 テクミラ ファーマシューティカルズ コーポレイション 核酸の送達のための改善された組成物および方法
US9226959B2 (en) 2008-01-31 2016-01-05 Curevac Ag Nucleic acids comprising formula (NuGlXmGnNv)a and derivatives thereof as immunostimulating agent/adjuvant
CA2721333C (en) 2008-04-15 2020-12-01 Protiva Biotherapeutics, Inc. Novel lipid formulations for nucleic acid delivery
PL215513B1 (pl) 2008-06-06 2013-12-31 Univ Warszawski Nowe boranofosforanowe analogi dinukleotydów, ich zastosowanie, czasteczka RNA, sposób otrzymywania RNA oraz sposób otrzymywania peptydów lub bialka
EP2161279A1 (en) 2008-08-29 2010-03-10 Centre National de la Recherche Scientifique Synthetic peptides corresponding to overlapping neutralizing determinants in the CBD1 epitope induce broadly neutralizing antibodies
WO2010037408A1 (en) 2008-09-30 2010-04-08 Curevac Gmbh Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof
JP5777519B2 (ja) 2008-10-09 2015-09-09 テクミラ ファーマシューティカルズ コーポレイション 改良されたアミノ脂質および核酸の送達方法
WO2010048536A2 (en) 2008-10-23 2010-04-29 Alnylam Pharmaceuticals, Inc. Processes for preparing lipids
CA3006395C (en) 2008-11-07 2022-05-31 Massachusetts Institute Of Technology Aminoalcohol lipidoids and uses thereof
PL2355851T3 (pl) 2008-11-10 2018-08-31 Arbutus Biopharma Corporation Nowe lipidy i kompozycje do dostarczania środków terapeutycznych
WO2010087791A1 (en) 2009-01-27 2010-08-05 Utc Power Corporation Distributively cooled, integrated water-gas shift reactor and vaporizer
EP3243504A1 (en) 2009-01-29 2017-11-15 Arbutus Biopharma Corporation Improved lipid formulation
CA2756996C (en) 2009-04-01 2018-12-11 University Of Miami Vaccine compositions and methods of use thereof
US8467858B2 (en) 2009-04-29 2013-06-18 Tomophase Corporation Image-guided thermotherapy based on selective tissue thermal treatment
US8883202B2 (en) 2009-05-05 2014-11-11 Tekmira Pharmaceuticals Corporation Lipid compositions
LT2440183T (lt) 2009-06-10 2018-08-10 Arbutus Biopharma Corporation Patobulinta lipido kompozicija
EP2281579A1 (en) 2009-08-05 2011-02-09 BioNTech AG Vaccine composition comprising 5'-Cap modified RNA
US20110053829A1 (en) 2009-09-03 2011-03-03 Curevac Gmbh Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids
WO2011069529A1 (en) 2009-12-09 2011-06-16 Curevac Gmbh Mannose-containing solution for lyophilization, transfection and/or injection of nucleic acids
CN103002878B (zh) 2010-04-09 2015-07-01 帕西拉制药有限公司 用于配制大直径合成膜囊泡的方法
NZ605079A (en) 2010-06-03 2015-08-28 Alnylam Pharmaceuticals Inc Biodegradable lipids for the delivery of active agents
PL2590626T3 (pl) 2010-07-06 2016-04-29 Glaxosmithkline Biologicals Sa Liposomy z lipidami o korzystnej wartości pka do dostarczania rna
CA2804591C (en) 2010-07-06 2019-01-22 Novartis Ag Cationic oil-in-water emulsions
CN107648604A (zh) 2010-07-30 2018-02-02 库瑞瓦格股份公司 聚合物载体运载物复合物及聚合物载体的用途
WO2012019630A1 (en) 2010-08-13 2012-02-16 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded protein
WO2012030901A1 (en) 2010-08-31 2012-03-08 Novartis Ag Small liposomes for delivery of immunogen-encoding rna
SI3970742T1 (sl) 2010-08-31 2022-08-31 Glaxosmithkline Biologicals S.A. Pegilirani liposomi za dostavo RNA, ki kodira imunogen
CN103384515B (zh) 2010-08-31 2017-02-15 诺华有限公司 适用于脂质体递送编码蛋白质的rna的脂质
WO2012089225A1 (en) 2010-12-29 2012-07-05 Curevac Gmbh Combination of vaccination and inhibition of mhc class i restricted antigen presentation
WO2012116715A1 (en) 2011-03-02 2012-09-07 Curevac Gmbh Vaccination in newborns and infants
WO2012113413A1 (en) 2011-02-21 2012-08-30 Curevac Gmbh Vaccine composition comprising complexed immunostimulatory nucleic acids and antigens packaged with disulfide-linked polyethyleneglycol/peptide conjugates
WO2012116714A1 (en) 2011-03-02 2012-09-07 Curevac Gmbh Vaccination in elderly patients
SG10201605537XA (en) 2011-07-06 2016-09-29 Novartis Ag Liposomes having useful n:p ratio for delivery of rna molecules
CN114835823A (zh) * 2011-07-29 2022-08-02 宾夕法尼亚大学董事会 转换共刺激受体
PT2750707T (pt) 2011-08-31 2019-01-23 Glaxosmithkline Biologicals Sa Lipossomas peguilados para distribuição de arn que codifica imunogénio
US8969545B2 (en) 2011-10-18 2015-03-03 Life Technologies Corporation Alkynyl-derivatized cap analogs, preparation and uses thereof
EP2623121A1 (en) 2012-01-31 2013-08-07 Bayer Innovation GmbH Pharmaceutical composition comprising a polymeric carrier cargo complex and an antigen
WO2013113326A1 (en) 2012-01-31 2013-08-08 Curevac Gmbh Pharmaceutical composition comprising a polymeric carrier cargo complex and at least one protein or peptide antigen
WO2013113325A1 (en) 2012-01-31 2013-08-08 Curevac Gmbh Negatively charged nucleic acid comprising complexes for immunostimulation
WO2013120497A1 (en) 2012-02-15 2013-08-22 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein
WO2013120500A1 (en) 2012-02-15 2013-08-22 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded tumour antigen
WO2013120499A1 (en) 2012-02-15 2013-08-22 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly (a) sequence or a polyadenylation signal for increasing the expression of an encoded pathogenic antigen
WO2013120498A1 (en) 2012-02-15 2013-08-22 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded allergenic antigen or an autoimmune self-antigen
SG10201607966UA (en) 2012-03-27 2016-11-29 Curevac Ag Artificial nucleic acid molecules comprising a 5'top utr
MX2019002345A (es) 2012-03-27 2022-08-24 Curevac Ag Moleculas artificiales de acido nucleico para la expresion mejorada de proteina o peptido.
CA2866955A1 (en) * 2012-03-27 2013-10-03 Curevac Gmbh Artificial nucleic acid molecules
GB2502127A (en) 2012-05-17 2013-11-20 Kymab Ltd Multivalent antibodies and in vivo methods for their production
ES2719598T3 (es) 2012-05-25 2019-07-11 Curevac Ag Inmovilización reversible y/o liberación controlada de ácidos nucleicos contenidos en nanopartículas mediante revestimientos poliméricos (biodegradables)
AU2013204922B2 (en) * 2012-12-20 2015-05-14 Celgene Corporation Chimeric antigen receptors
MX385338B (es) 2013-02-22 2025-03-18 CureVac SE Combinación de vacunación e inhibición de la trayectoria pd-1.
AU2014310932B2 (en) 2013-08-21 2019-06-06 CureVac SE Composition and vaccine for treating lung cancer
WO2015024669A1 (en) 2013-08-21 2015-02-26 Curevac Gmbh Combination vaccine
KR20160043103A (ko) 2013-08-21 2016-04-20 큐어백 아게 전립선암 치료를 위한 조성물 및 백신
ES2747762T3 (es) 2013-08-21 2020-03-11 Curevac Ag Vacuna contra el virus respiratorio sincitial (RSV)
WO2015024665A1 (en) 2013-08-21 2015-02-26 Curevac Gmbh Rabies vaccine
MX2016002152A (es) 2013-08-21 2017-01-05 Curevac Ag Metodo para aumentar la expresion de proteinas codificadas por arn.
EP3041938A1 (en) 2013-09-03 2016-07-13 Moderna Therapeutics, Inc. Circular polynucleotides
ES2806575T3 (es) 2013-11-01 2021-02-18 Curevac Ag ARN modificado con propiedades inmunoestimuladoras disminuidas
JP6486955B2 (ja) 2013-11-18 2019-03-20 アークトゥルス セラピューティクス， インコーポレイテッド Ｒｎａ送達のためのイオン化可能なカチオン性脂質
GB201321384D0 (en) * 2013-12-04 2014-01-15 Isis Innovation Molecular adjuvant
WO2015100219A1 (en) * 2013-12-23 2015-07-02 Oncomed Pharmaceuticals, Inc. Immunotherapy with binding agents
JP6704850B2 (ja) 2013-12-30 2020-06-03 キュアバック アーゲー 人工核酸分子
JP6584414B2 (ja) 2013-12-30 2019-10-02 キュアバック アーゲー 人工核酸分子
SG10201805660WA (en) 2013-12-30 2018-08-30 Curevac Ag Methods for rna analysis
EP4303229A3 (en) * 2014-01-21 2024-04-17 Novartis AG Enhanced antigen presenting ability of car t cells by co-introduction of costimulatory molecules
ES2754239T3 (es) 2014-03-12 2020-04-16 Curevac Ag Combinación de vacunación y agonistas de OX40
WO2015149944A2 (en) 2014-04-01 2015-10-08 Curevac Gmbh Polymeric carrier cargo complex for use as an immunostimulating agent or as an adjuvant
PL3155129T3 (pl) 2014-06-10 2019-09-30 Curevac Ag Sposób zwiększania wytwarzania RNA
IL298516B2 (en) 2014-06-25 2025-03-01 Acuitas Therapeutics Inc Novel lipids and lipid nanoparticle compositions for nucleic acid delivery
EP3169335B8 (en) 2014-07-16 2019-10-09 ModernaTX, Inc. Circular polynucleotides
BR112017005390A2 (pt) * 2014-09-17 2017-12-12 Novartis Ag células citotóxicas alvo com receptores quiméricos para imunoterapia adotiva
DK3708668T3 (da) 2014-12-12 2022-09-26 Curevac Ag Kunstigt nukleinsyremolekyle til forbedret proteinudtrykkelse
CA2962849A1 (en) 2014-12-16 2016-06-23 Curevac Ag Ebolavirus and marburgvirus vaccines
WO2016107877A1 (en) 2014-12-30 2016-07-07 Curevac Ag Artificial nucleic acid molecules
EP3247363A4 (en) 2015-01-21 2018-10-03 Moderna Therapeutics, Inc. Lipid nanoparticle compositions
WO2016118725A1 (en) 2015-01-23 2016-07-28 Moderna Therapeutics, Inc. Lipid nanoparticle compositions
EP3283059B1 (en) 2015-04-13 2024-01-03 CureVac Manufacturing GmbH Method for producing rna compositions
EP3283125B1 (en) 2015-04-17 2021-12-29 CureVac Real Estate GmbH Lyophilization of rna
AU2016251687C1 (en) 2015-04-22 2023-07-27 CureVac SE RNA containing composition for treatment of tumor diseases
EP3289077B1 (en) 2015-04-30 2020-04-15 CureVac AG Method for in vitro transcription using an immobilized restriction enzyme
ES2897823T3 (es) 2015-04-30 2022-03-02 Curevac Ag Poli(N)polimerasa inmovilizada
EP3294885B1 (en) 2015-05-08 2020-07-01 CureVac Real Estate GmbH Method for producing rna
US11559570B2 (en) 2015-05-15 2023-01-24 CureVac SE Prime-boost regimens involving administration of at least one mRNA construct
EP3297682B1 (en) 2015-05-20 2021-07-14 CureVac AG Dry powder composition comprising long-chain rna
WO2016184575A1 (en) 2015-05-20 2016-11-24 Curevac Ag Dry powder composition comprising long-chain rna
WO2016193226A1 (en) 2015-05-29 2016-12-08 Curevac Ag Method for adding cap structures to rna using immobilized enzymes
DE202016009003U1 (de) 2015-05-29 2021-05-28 Curevac Real Estate Gmbh Zusammensetzung umfassend in vitro transkribierte RNA erhältlich durch ein Verfahren zur Herstellung und Reinigung von RNA mit mindestens einem Schritt mit einer tangentialen Flussfiltration
WO2016203025A1 (en) * 2015-06-17 2016-12-22 Curevac Ag Vaccine composition
US20190017100A1 (en) 2015-07-01 2019-01-17 Curevac Ag Method for analysis of an rna molecule
WO2017009376A1 (en) 2015-07-13 2017-01-19 Curevac Ag Method of producing rna from circular dna and corresponding template dna
WO2017021546A1 (en) 2015-08-05 2017-02-09 Curevac Ag Epidermal mrna vaccine
DK3332019T3 (da) 2015-08-07 2020-02-17 Curevac Ag Fremgangsmåde til in vivo-produktionen af rna i en værtscelle
DK3334828T3 (en) 2015-08-10 2020-12-14 Curevac Real Estate Gmbh Fremgangsmåde til at øge replikationen af et cirkulært dna-molekyle
EP4424835A3 (en) 2015-09-21 2024-10-23 TriLink BioTechnologies, LLC Compositions and methods for synthesizing 5'-capped rnas
EP3362576A1 (en) 2015-10-12 2018-08-22 CureVac AG Automated method for isolation, selection and/or detection of microorganisms or cells comprised in a solution
US20190218546A1 (en) 2015-10-16 2019-07-18 Modernatx, Inc. Mrna cap analogs with modified phosphate linkage
US11866754B2 (en) 2015-10-16 2024-01-09 Modernatx, Inc. Trinucleotide mRNA cap analogs
WO2017066791A1 (en) 2015-10-16 2017-04-20 Modernatx, Inc. Sugar substituted mrna cap analogs
WO2017066789A1 (en) 2015-10-16 2017-04-20 Modernatx, Inc. Mrna cap analogs with modified sugar
WO2017066782A1 (en) 2015-10-16 2017-04-20 Modernatx, Inc. Hydrophobic mrna cap analogs
CA3001014A1 (en) 2015-10-16 2017-04-20 Modernatx, Inc. Mrna cap analogs and methods of mrna capping
CN118846026A (zh) 2015-10-22 2024-10-29 摩登纳特斯有限公司 广谱流感病毒疫苗
JP6921833B2 (ja) 2015-10-22 2021-08-18 モデルナティーエックス， インコーポレイテッド ヒトサイトメガロウイルスワクチン
EP4582098A3 (en) 2015-11-09 2025-12-24 CureVac SE Optimized nucleic acid molecules
US11413346B2 (en) 2015-11-09 2022-08-16 Curevac Ag Rotavirus vaccines
WO2017099823A1 (en) 2015-12-10 2017-06-15 Modernatx, Inc. Compositions and methods for delivery of therapeutic agents
EP3394237A1 (en) 2015-12-21 2018-10-31 CureVac AG Inlay for a culture plate and corresponding method for preparing a culture plate system with such inlay
EP4036079B1 (en) 2015-12-22 2025-11-19 ModernaTX, Inc. Compounds and compositions for intracellular delivery of agents
US11684665B2 (en) 2015-12-22 2023-06-27 CureVac SE Method for producing RNA molecule compositions
US11248223B2 (en) 2015-12-23 2022-02-15 Curevac Ag Method of RNA in vitro transcription using a buffer containing a dicarboxylic acid or tricarboxylic acid or a salt thereof
US9834510B2 (en) 2015-12-30 2017-12-05 Arcturus Therapeutics, Inc. Aromatic ionizable cationic lipid
US20210180106A1 (en) 2016-02-12 2021-06-17 Curevac Ag Method for analyzing rna
US20190049414A1 (en) 2016-02-15 2019-02-14 Curevac Ag Method for analyzing by-products of rna in vitro transcription
WO2017140905A1 (en) 2016-02-17 2017-08-24 Curevac Ag Zika virus vaccine
WO2017149139A1 (en) 2016-03-03 2017-09-08 Curevac Ag Rna analysis by total hydrolysis
WO2017162297A1 (en) 2016-03-24 2017-09-28 Curevac Ag Immobilized inorganic pyrophosphatase (ppase)
US20180237789A1 (en) 2016-04-16 2018-08-23 Jiangnan University Mortierella alpine uracil auxotroph with ura5 gene knocked out through homologous recombination
EP4487869A3 (en) 2016-04-22 2025-07-30 CureVac SE Rna encoding a tumor antigen
EP3448427A1 (en) 2016-04-29 2019-03-06 CureVac AG Rna encoding an antibody
EP3452101A2 (en) 2016-05-04 2019-03-13 CureVac AG Rna encoding a therapeutic protein
US20180126003A1 (en) 2016-05-04 2018-05-10 Curevac Ag New targets for rna therapeutics
EP3452086A1 (en) 2016-05-04 2019-03-13 CureVac AG Influenza mrna vaccines
US11141474B2 (en) 2016-05-04 2021-10-12 Curevac Ag Artificial nucleic acid molecules encoding a norovirus antigen and uses thereof
WO2017203008A1 (en) 2016-05-25 2017-11-30 Curevac Ag Novel biomarkers
US20190336608A1 (en) 2016-06-09 2019-11-07 Curevac Ag Cationic carriers for nucleic acid delivery
WO2017212008A1 (en) 2016-06-09 2017-12-14 Curevac Ag Hybrid carriers for nucleic acid cargo
EP3468608A1 (en) 2016-06-09 2019-04-17 CureVac AG Hybrid carriers for nucleic acid cargo
BR112018075479A2 (pt) 2016-06-09 2019-03-19 Curevac Ag portadores híbridos para carga de ácido nucleico
BR112019000598A2 (pt) 2016-08-19 2019-07-02 Curevac Ag rna para terapia de câncer
WO2018058088A1 (en) * 2016-09-26 2018-03-29 SOLA Biosciences, LLC Cell-associated secretion-enhancing fusion proteins
US10487105B2 (en) 2016-10-19 2019-11-26 Arcturus Therapeutics, Inc. Trinucleotide MRNA cap analogs
US20200163878A1 (en) 2016-10-26 2020-05-28 Curevac Ag Lipid nanoparticle mrna vaccines

Also Published As

Publication number Publication date
EP4494652A2 (en) 2025-01-22
KR102761594B1 (ko) 2025-02-03
ES3013993T3 (en) 2025-04-16
EP3424524A2 (en) 2019-01-09
JP2023123739A (ja) 2023-09-05
US20190040378A1 (en) 2019-02-07
JP2020530980A (ja) 2020-11-05
EP3424524B1 (en) 2024-12-11
CN111328287A (zh) 2020-06-23
JP7722629B2 (ja) 2025-08-13
WO2019008001A1 (en) 2019-01-10
KR20200024905A (ko) 2020-03-09
CA3066932A1 (en) 2019-01-10
RU2020103379A (ru) 2021-08-04
US20210198649A1 (en) 2021-07-01
US10988754B2 (en) 2021-04-27
AU2018298422A1 (en) 2019-12-19
BR112019028280A2 (pt) 2020-07-14
EP3424524A3 (en) 2019-02-27
AU2018298422B2 (en) 2023-04-06
EP4494652A3 (en) 2025-05-14
EP3648791A1 (en) 2020-05-13
SG11201911430PA (en) 2020-01-30

Similar Documents

Publication Publication Date Title
BR122021024395A2 (cg-RX-API-DMAC7.html)
RU2020103379A3 (cg-RX-API-DMAC7.html)
BR112020006084A8 (cg-RX-API-DMAC7.html)
BR122022025811B8 (cg-RX-API-DMAC7.html)
BR202018014992U2 (cg-RX-API-DMAC7.html)
BR122021023687A2 (cg-RX-API-DMAC7.html)
BR122021014832A2 (cg-RX-API-DMAC7.html)
BR122022003522A2 (cg-RX-API-DMAC7.html)
BR202017021228U2 (cg-RX-API-DMAC7.html)
BR202017020981U2 (cg-RX-API-DMAC7.html)
BR202017017068U2 (cg-RX-API-DMAC7.html)
BR202017016984U2 (cg-RX-API-DMAC7.html)
BR202017016924U2 (cg-RX-API-DMAC7.html)
BR202017012548U2 (cg-RX-API-DMAC7.html)
BR202017011220U2 (cg-RX-API-DMAC7.html)
BR202017010814U2 (cg-RX-API-DMAC7.html)
BR202017010373U2 (cg-RX-API-DMAC7.html)
BR202017009870U2 (cg-RX-API-DMAC7.html)
BR202017006953U2 (cg-RX-API-DMAC7.html)
BR202017004898U2 (cg-RX-API-DMAC7.html)
BR202017002937U2 (cg-RX-API-DMAC7.html)
BR202017002826U2 (cg-RX-API-DMAC7.html)
CN303998501S (cg-RX-API-DMAC7.html)
CN303995942S (cg-RX-API-DMAC7.html)
CN303998498S (cg-RX-API-DMAC7.html)